| pubmed-article:2543557 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2543557 | lifeskim:mentions | umls-concept:C0521390 | lld:lifeskim |
| pubmed-article:2543557 | lifeskim:mentions | umls-concept:C0022471 | lld:lifeskim |
| pubmed-article:2543557 | lifeskim:mentions | umls-concept:C0598695 | lld:lifeskim |
| pubmed-article:2543557 | lifeskim:mentions | umls-concept:C0279023 | lld:lifeskim |
| pubmed-article:2543557 | lifeskim:mentions | umls-concept:C1883709 | lld:lifeskim |
| pubmed-article:2543557 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2543557 | pubmed:dateCreated | 1989-7-18 | lld:pubmed |
| pubmed-article:2543557 | pubmed:abstractText | The time course and severity of the excitotoxic syndrome induced in rats by s.c. injection of 10 mg/kg kainic acid (KA) was modified by pretreatment with MK801, a non-competitive inhibitor of the NMDA receptor, at doses of 0.1, 1 and 10 mg/kg. A dose-dependent increase in the severity of the KA-induced electrographic (EEG) manifestations of epilepsy was seen after MK801. This consisted of an earlier appearance and higher number of EEG seizures, longer time spent in seizures, and an earlier onset of status epilepticus. In contrast, behavioral seizures were increased only in the 0.1 mg/kg MK801 group, but abolished by higher doses. On the contrary, wet dog shakes were progressively reduced with increasing doses of MK801. Four of the 9 animals receiving KA-only group and 3 of the 10 animals in the 1 and 10 mg MK801 groups were sacrificed 5 days after KA. The brain of the KA-only rats presented diffuse gross and microscopic evidence of hemorrhagic necrosis and neuronal damage; the MK801 rats showed only minimal neuronal loss in the CA3 hippocampal sector. This study demonstrates that neuronal damage and epileptiform activity can be dissociated. Furthermore, it confirms the protective effect of MK801 against neuronal damage caused by multiple factors. Lastly, it emphasizes the need for EEG monitoring in order to accurately assess any epileptic/antiepileptic effect. | lld:pubmed |
| pubmed-article:2543557 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2543557 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2543557 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2543557 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2543557 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2543557 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2543557 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2543557 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2543557 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2543557 | pubmed:issn | 0920-1211 | lld:pubmed |
| pubmed-article:2543557 | pubmed:author | pubmed-author:SmithG GGG | lld:pubmed |
| pubmed-article:2543557 | pubmed:author | pubmed-author:FarielloR GRG | lld:pubmed |
| pubmed-article:2543557 | pubmed:author | pubmed-author:GoldenG TGT | lld:pubmed |
| pubmed-article:2543557 | pubmed:author | pubmed-author:ReyesP FPF | lld:pubmed |
| pubmed-article:2543557 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2543557 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:2543557 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2543557 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2543557 | pubmed:pagination | 206-13 | lld:pubmed |
| pubmed-article:2543557 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:meshHeading | pubmed-meshheading:2543557-... | lld:pubmed |
| pubmed-article:2543557 | pubmed:articleTitle | Potentiation of kainic acid epileptogenicity and sparing from neuronal damage by an NMDA receptor antagonist. | lld:pubmed |
| pubmed-article:2543557 | pubmed:affiliation | Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612. | lld:pubmed |
| pubmed-article:2543557 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2543557 | lld:pubmed |
